Table 3.
Laboratory findings of COVID‐19 patients on admission to hospital
| Median (IQR) | |||||
|---|---|---|---|---|---|
| Blood routine | Normal range | Total (n = 56) | Severe (n = 34) | Nonsevere (n = 22) | P |
| Leukocytes, ×109/L | 3.5‐9.5 | 5.61 (4.54‐7.16) | 6.46 (4.67‐7.51) | 5.13 (4.46‐5.98) | .0685 |
| Neutrophils, ×109/L | 1.8‐6.3 | 3.33 (2.63‐4.68) | 4.31 (2.88‐5.47) | 2.78 (2.35‐3.56) | .001** |
| Percentage of neutrophils, % | 40‐75.0 | 63.26 (56.26‐69.23) | 64.74 (61.6‐73.82) | 56.31 (50.07‐63.96) | .0001*** |
| Lymphocytes, ×109/L | 1.1‐3.2 | 1.44 (1.06‐1.75) | 1.22 (0.93‐1.68) | 1.62 (1.31‐1.88) | .008** |
| Percentage of lymphocytes, % | 20‐50.0 | 24.65 (19.08‐31.15) | 21.65 (15.88‐25.25) | 30.35 (26‐34.78) | <.0001**** |
| Platelets, ×109/L | 125‐350.0 | 204.5 (157.5‐262.8) | 210 (154.5‐308.8) | 204.5 (161‐243) | .5856 |
| Hemoglobin, g/L | 115‐150.0 | 120 (116.0‐131.0) | 125 (117.0‐135.0) | 117.5 (113.3‐120.5) | .0185* |
| CD3, % | 58.17‐84.22 | 75 (70.57‐79.61) | 74.68 (70.81‐78.92) | 77.18 (68.35‐82.03) | .2459 |
| CD4, % | 25.34‐51.37 | 45.49 (40.59‐52.52) | 44.92 (40.46‐53.49) | 46.29 (40.7‐52.36) | .9303 |
| CD8, % | 14.23‐38.95 | 24.56 (17.37‐30.52) | 23.52 (17.8‐30.23) | 25.16 (16.15‐31.41) | .9967 |
| CD4/CD8 | 0.41‐2.72 | 1.94 (1.42‐2.88) | 1.88 (1.39‐2.85) | 1.99 (1.52‐3.19) | .8581 |
| Coagulation function | |||||
| Activated partial thromboplastin time, s | 28‐43.5 | 35.6 (32.90‐38.45) | 36 (34.05‐39.85) | 34.15 (32.48‐36.95) | .0802 |
| Prothrombin time, s | 11‐16.0 | 13.25 (12.80‐13.78) | 13.4 (12.68‐13.9) | 13.1 (12.8‐13.6) | .3388 |
| D‐dimer, mg/L | <0.5 | 0.43 (0.22‐0.80) | 0.59 (0.22‐1.0) | 0.34 (0.22‐0.54) | .1796 |
| Fibrinogen, g/L | 2.0‐4.0 | 4.06 (3.13‐5.25) | 4.51 (3.39‐5.45) | 3.51 (2.90‐4.39) | .0154* |
| Blood biochemistry | |||||
| Alanine aminotransferase, IU/L | 8‐40.0 | 30.5 (20‐52.75) | 33.5 (21‐62.75) | 26 (17.5‐43.5) | .3974 |
| Aspartate aminotransferase, IU/L | 5‐35.0 | 26.50 (21‐39.25) | 28 (22‐40.75) | 23.5 (18.75‐36.75) | .1794 |
| Serum creatinine, μmol/L | 44‐106.0 | 69.5 (62‐79.75) | 70.95 (60.75‐84) | 67.95 (62‐77.5) | .4407 |
| Creatine kinase, IU/L | 22.0‐269.0 | 52 (33.25‐70.75) | 50.5 (33‐73.25) | 52 (37‐62.75) | .9635 |
| Creatine kinase‐MB, ng/mL | <6.6 | 0.5 (0.3‐0.7) | 0.45 (0.3‐0.7) | 0.5 (0.3‐0.93) | .4376 |
| Lactate dehydrogenase, U/L | 109‐245.0 | 194 (155‐232.5) | 200 (168‐244) | 188 (145.8‐206.8) | .1223 |
| Hypersensitive troponin I, ng/L | <26.2 | 2.15 (1.2‐4.38) | 3 (1.2‐5.9) | 1.6 (1.08‐3.43) | .0994 |
| Infection‐related biomarkers | |||||
| C‐reactive protein, mg/L | 0‐8.0 | 33.1 (11.83‐67.45) | 33.1 (15.40‐80.20) | 30.08 (8.26‐51.9) | 0.8235 |
| Hypersensitive C‐reactive protein, mg/L | <4.0 | 1.9 (0.98‐3.31) | 2.61 (1.56‐3.69) | 1.25 (0.08‐2.5) | .147 |
| Procalcitonin, ng/mL | 0‐0.5 | 0.2 (0.19‐0.21) | 0.2 (0.19‐0.21) | <0.13 | / |
Note: Data are presented as the median (interquartile range [IQR]). Statistical analysis was performed using the Mann‐Whitney test. P values indicate differences between severe and nonsevere patients. *P < .05 was considered statistically significant.
Abbreviation: COVID‐19, coronavirus disease.
*P < .05. **P < .005. ***P < .001. ****P < .0001.